Skip NavigationSkip to Content

Cytosolic d-type CpG-oligonucleotides induce a type I interferon response by activating the cGAS-STING signaling pathway

  1. Author:
    Bode, Christian
    Poth, Jens M.
    Fox, Mario
    Schulz, Susanne
    Klinman, Dennis M.
    Latz, Eicke
    Steinhagen, Folkert
  2. Author Address

    Univ Hosp Bonn, Dept Anesthesiol & Intens Care Med, Bonn, Germany.NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD USA.Univ Hosp Bonn, Inst Innate Immun, Bonn, Germany.SHG Clin Voelklingen, Dept Anesthesiol & Intens Care Med, Voelklingen, Germany.
    1. Year: 2021
    2. Date: May 12
  1. Journal: European Journal of Immunology
  2. Wiley
    1. 51
    2. 7
    3. Pages: 1686-1697
  3. Type of Article: Article
  4. ISSN: 0014-2980
  1. Abstract:

    Cytosolic DNA receptor cyclic GMP-AMP (cGAMP) synthase (cGAS) has been shown to be critically involved in the detection of cytosolic, self- and non-self-DNA, initiating a type I IFN response through the adaptor protein Stimulator of Interferon Genes (STING) and interferon regulatory factor 3 (IRF3). Current studies propose that canonical binding of dsDNA by cGAS depends on DNA length, but not on base sequence. In contrast, activation of TLR9 is sequence dependent. It requires unmethylated CpG dinucleotides in microbial DNA, which is mimicked by synthetic oligodeoxynucleotides (ODN). Here, we provide evidence that d-type ODN (D-ODN), but not K-type ODN (K-ODN), bind to human cGAS and activate downstream signaling. Transfection of D-ODN into a TLR9-deficient, human monocytic cell line (THP-1) induced phosphorylation of IRF3 and secretion of IFN. This response was absent in cells with CRISPR/Cas9-mediated cGAS- or STING-deficiency. Utilizing a protein pulldown approach, we further demonstrate direct binding of D-ODN to cGAS. Induction of a type I IFN response by D-ODN was confirmed in human primary monocytes and monocyte-derived macrophages. These results are relevant to our understanding of self-nonself-discrimination by cGAS and to the pharmacologic effects of ODN, which currently are investigated in clinical studies.

    See More

External Sources

  1. DOI: 10.1002/eji.202048810
  2. PMID: 33860535
  3. WOS: 000649255200001

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel